Heath-related quality of life in thyroid cancer patients following radioiodine ablation

Health and Quality of Life Outcomes

Volumn 9, Issue , 2011, Pages

  Taïeb, David ^a   Baumstarck Barrau, Karine ^b   Sebag, Frédéric ^a   Fortanier, Cécile ^b   De Micco, Catherine ^c   Loundou, Anderson ^b   Auquier, Pascal ^d   Palazzo, Fausto F ^a   Henry, Jean François ^a   Mundler, Olivier ^a  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSERM   (France)

^d HÔPITAL NORD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROTROPIN;

ABLATION THERAPY; ADULT; ANXIETY; ARTICLE; CANCER SURGERY; CLINICAL ASSESSMENT; DEPRESSION; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS AND THERAPY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; QUALITY OF LIFE; RADIOIODINE ABLATION; SCORING SYSTEM; THYROID CANCER; THYROIDECTOMY; TREATMENT DURATION; AGED; HEALTH STATUS; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; SOCIOECONOMICS; THYROID TUMOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEALTH STATUS; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; QUALITY OF LIFE; SOCIOECONOMIC FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955801372     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-9-33     Document Type: Article

References (26)

1. Borson-Chazot F, Bardet S, Bournaud C, Conte-Devolx B, Corone C, D'Herbomez M, Henry JF, Leenhardt L, Peix JL, Schlumberger M, Wemeau JL, Baudin E, Berger N, Bernard MH, Calzada-Nocaudie M, Caron P, Catargi B, Chabrier G, Charrie A, Franc B, Hartl D, Helal B, Kerlan V, Kraimps JL, Leboulleux S, Le Clech G, Menegaux F, Orgiazzi J, Perie S, Raingeard I, et al. Guidelines for the management of differentiated thyroid carcinomas of vesicular origin. Ann Endocrinol (Paris) 2008, 69:472-486.
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. 75-Thyroid 2009, 19:1167-1214.
3. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16:109-142. 10.1089/thy.2006.16.109, 16420177.
4. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008, 35:1941-1959. 10.1007/s00259-008-0883-1, 18670773.
5. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006, 154:787-803. 10.1530/eje.1.02158, 16728537.
6. Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JW, Sanchez Franco F, Lind P, Limbert E, Jarzab B, Jamar F, Duntas L, Cohen O, Berg G. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004, 151:539-548. 10.1530/eje.0.1510539, 15538930.
7. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006, 91:926-932.
8. Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry JF, Mundler O. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf) 2009, 71:115-123.
9. Almeida JP, Vartanian JG, Kowalski LP. Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. Arch Otolaryngol Head Neck Surg 2009, 135:342-346. 10.1001/archoto.2009.16, 19380354.
10. Hoftijzer HC, Heemstra KA, Corssmit EP, van der Klaauw AA, Romijn JA, Smit JW. Quality of life in cured patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008, 93:200-203.
11. Malterling RR, Andersson RE, Falkmer S, Falkmer U, Nilehn E, Jarhult J. Differentiated thyroid cancer in a Swedish county - long-term results and quality of life. Acta Oncol 49(4):454-9.
12. Pelttari H, Sintonen H, Schalin-Jantti C, Valimaki MJ. Health-related quality of life in long-term follow-up of patients with cured TNM Stage I or II differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2009, 70:493-497.
13. Tagay S, Herpertz S, Langkafel M, Erim Y, Bockisch A, Senf W, Gorges R. Health-related Quality of Life, depression and anxiety in thyroid cancer patients. Qual Life Res 2006, 15:695-703. 10.1007/s11136-005-3689-7, 16688502.
14. Tan LG, Nan L, Thumboo J, Sundram F, Tan LK. Health-related quality of life in thyroid cancer survivors. Laryngoscope 2007, 117:507-510. 10.1097/MLG.0b013e31802e3739, 17334313.
15. Chow SM, Au KH, Choy TS, Lee SH, Yeung NY, Leung A, Leung A, Leung HL, Shek CC, Law SC. Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning. Laryngoscope 2006, 116:2060-2066. 10.1097/01.mlg.0000240287.57704.01, 17075410.
16. Eustatia-Rutten CF, Corssmit EP, Pereira AM, Frolich M, Bax JJ, Romijn JA, Smit JW. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin Endocrinol (Oxf) 2006, 64:284-291.
17. Spielberger C. Manual for the state-trait anxiety inventory (form Y). Palo Alto, CA: consulting psychologists 1983,
18. Spielberger C, RL G, Lushene R. Manual for the state-trait anxiety inventory (Self-evaluation questionnaire). Palo Alto, CA: consulting psychologists 1970,
19. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
20. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997, 34:13-19.
21. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993, 11:570-579.
22. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997, 13:63-74.
23. Greenacre M, Blasius J. Multiple Correspondence Analysis and Related Methods. 2006, London: Chapman and Hall/CRC.
24. Panagiotakos DB, Pitsavos C. Interpretation of epidemiological data using multiple correspondence analysis and log-linear models. J Data Sci 2004, 2:75-86.
25. Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, Vincent M, Legrand C, van Meerbeeck JP. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 2007, 25:5770-5776. 10.1200/JCO.2007.12.5294, 18089874.
26. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989, 27:S217-232. 10.1097/00005650-198903001-00018, 2646490.